Catalent Pharma Solutions has signed an agreement with Zhejiang HISUN Pharmaceuticals Co. Ltd. (HISUN), to provide HISUN with a broad range of biosimilar cell lines, using Catalent's proprietary GPEx^® technology for the Chinese market. Under the agreement, HISUN will produce a broad range of biosimilars, including infliximab, adalimumab and alemtuzumab, using Catalent's GPEx cell lines. The GPEx technology is used to create mammalian cell lines.  

In 2013, Catalent announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses to support customers within the Asia-Pacific region. Since then, the company has completed the acquisition of a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Co. Ltd., and continues to invest in its softgel business.  Catalent's opened a new 31,000-square foot  ft facility in Shanghai in November 2013 to provide end-to-end solutions for clinical trial supplies.

Source: Catalent Pharma Solutions